Please login to the form below
Statutory scheme
This page shows the latest Statutory scheme news and features for those working in and with pharma, biotech and healthcare.
AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
Both companies will now come under the scheme imposed by the government through law. ... The companies will now come under the alternative statutory scheme imposed by the government through law, demonstrating what the ABPI describes as 'the depth of
Latest news
-
NICE appraisal fees to be introduced despite opposition
The ABPI had suggested an alternative solution to the fees question, in which rebates from this scheme (or the parallel statutory scheme) would be paid annually by the industry as a ... However the DHSC concluded this arrangement was “outside its
-
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake
The industry hasn’t had a great deal of bargaining power in the talks – making the ‘voluntary’ title of the scheme more than a little ironic. ... Its name reflects its contrast to a parallel Statutory Scheme, which a number of companies have
-
Health secretary’s ‘rip off’ remarks anger UK pharma
Last month it unveiled plans for an updated Statutory Scheme, a ‘back up’ plan for companies not in the main PPRS pricing system.
-
ABPI hits out at ‘punitive’ UK medicines cost controls
Yesterday saw the government unveil its plans for an updated Statutory Scheme, a ‘back up’ plan for companies not in the main PPRS pricing system. ... Biosimilars also squeezed. The consultation also contain plans to bring biosimilar products into
-
UK unveils plans for bigger medicines price squeeze
Now, reviewing it in parallel with the new PPRS deal, the government wants to wring more savings out of the statutory scheme. ... uptake of new medicines guarantees – rather than just the ‘stick’ of increased revenue and profit controls laid out in
More from news
Approximately 2 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
The UK’s new medicines pricing deal – opportunities and risks for pharma
There are differences this time around, with the calculations including sales in the VPAS, the statutory scheme, and parallel imports. ... Industry saw these changes as a way to make the Statutory Scheme a poor alternative to the VPAS.
-
The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
the government dictates, or forcing all companies into a statutory scheme, is as false as the threat to reduce the cost-effectiveness threshold. ... challenge the government to force all companies into the statutory scheme, and negotiate on equal terms
-
The UK’s new five-year pricing agreement
A new cap mechanism to improve ‘stability’, which takes into account overall branded medicine sales across the voluntary and statutory schemes and parallel imports, although scheme members only pay for the ... Read the full 2019 Voluntary Scheme for
-
Comment: the new UK pricing deal – welcome news, but lessons to be learned
the Government dictates, or forcing all companies into a statutory scheme, is as false as the threat to reduce the cost-effectiveness threshold. ... challenge the Government to force all companies into the statutory scheme, and negotiate on equal terms
-
Brexit: can pharma 'take back control' of the narrative?
Another example is the recent consultation on the Statutory Scheme for branded medicines, which seems to directly contradict Government reassurances the sector has received about its importance post-Brexit.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
